MAHWAH, N.J., March 23, 2012 \/PRNewswire\/ -- HepatoChem, Inc, a chemistry-based technology platform company with a primary focus on metabolite production from bioactive small molecules, and an investment holding of Heartland Bridge Capital, Inc. (OTCBB: HLBC.OB - News), announced that it will present at the Early-Stage Life Sciences Technology Conference VIII at the Merck Research Laboratories in Boston, MA, on April 12, 2012. <\/p>\n
The Early-Stage Life Sciences Technology Conference will showcase 20 life sciences technologies developed at the universities, research institutions, and hospitals of Massachusetts and recently formed Massachusetts companies to an audience of angel investors, venture capitalists and corporate investors. http:\/\/www.mattcenter.org\/lsconf2012\/<\/a> <\/p>\n HepatoChem recently moved to its new laboratory in Beverly, MA. This is an important step for HepatoChem, which is committed to offering unique metabolite production services. This laboratory is part of the NorthShore Biotech Innoventure. <\/p>\n About HepatoChem, Inc <\/p>\n HepatoChem is a chemistry-based technology platform company with a primary focus on metabolite production from bioactive small molecules. Founded by Marc Bazin, previously with Pfizer, Inc., and Prof. John T. Groves, the Hugh Stott Taylor Chair of Chemistry at Princeton University, HepatoChem is dedicated to developing technologies that help pharmaceutical companies improve the quality of drug development pipelines. HepatoChem offers a unique and powerful solution to resolve the traditional lack of rapid and efficient metabolite access in drug discovery. http:\/\/www.hepatochem.com<\/a> <\/p>\n About Heartland Bridge Capital, Inc. <\/p>\n Heartland Bridge Capital, Inc. (OTCBB:HLBC.OB - News) is a public company that, in addition to managing its own operating entities, participates in emerging companies run by exceptionally talented entrepreneurs and operating executives who are dedicated to creating positive change in our world. HLBC functions as an owner, product developer, and investor focused primarily on providing equity, acquisition debt, or bridge financing to emerging high-growth companies and entrepreneurs in the areas of clean energy, waste management, and life sciences. http:\/\/www.heartlandbridgecapital.com<\/a>. <\/p>\n To request an investor packet, or to receive updates on Heartland Bridge Capital register online at http:\/\/www.wallstreetnewscast.com\/request\/hlbc.html<\/a> <\/p>\n Safe Harbor Notice <\/p>\n Certain statements contained herein are \"forward-looking statements\" (as defined in the Private Securities Litigation Reform Act of 1995). Heartland Bridge Capital, Inc. cautions that statements made in this news release relating to the investment in HepatoChem, and potential investment in and the business direction of the Company, constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates, and assumptions made by management. Actual results could differ materially from current projections or implied results. Heartland Bridge Capital, Inc. undertakes no obligation to revise these statements following the date of this news release. <\/p>\n<\/p>\n Read this article: MAHWAH, N.J., March 23, 2012 \/PRNewswire\/ -- HepatoChem, Inc, a chemistry-based technology platform company with a primary focus on metabolite production from bioactive small molecules, and an investment holding of Heartland Bridge Capital, Inc. (OTCBB: HLBC.OB - News), announced that it will present at the Early-Stage Life Sciences Technology Conference VIII at the Merck Research Laboratories in Boston, MA, on April 12, 2012 Continue reading
\nHepatoChem to Present at Early-Stage Life Sciences Technology Conference VIII<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"